AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24176498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tritanrix HB+Hib (first dose) and Quinvaxem (second/third doses)
Number of subjects: 400
Study 24176498 — intervention group
Group type: COMPARATOR
Intervention: Quinvaxem (three doses)
Number of subjects: 400
Study 24176498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tritanrix HB+Hib followed by Quinvaxem
Number of subjects: 400
Study 24176498 — intervention group
Group type: COMPARATOR
Intervention: Quinvaxem only
Number of subjects: 400
Study 22406868 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with retinyl palmitate on the first day postpartum
Number of subjects: 96
Study 22406868 — intervention group
Group type: COMPARATOR
Intervention: Control group (not supplemented)
Number of subjects: 96
Study 22406868 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with retinyl palmitate
Number of subjects: 96
Study 20529401 — intervention group
Group type: EXPERIMENTAL
Intervention: MM supplement with improved gruel (MMGG)
Number of subjects: 131
Study 20529401 — intervention group
Group type: COMPARATOR
Intervention: Improved gruel only (GG)
Number of subjects: 131
Study 19001507 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal-pressure-guided mechanical ventilation
Number of subjects: 61
Study 19001507 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care mechanical ventilation (control group)
Number of subjects: 61
Study 16158151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten Steps to Healthy Feeding intervention
Number of subjects: 500
Study 12608492 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg/day
Number of subjects: 183
Study 12608492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 11083688 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol (doubling methacholine concentrations)
Number of subjects: 410
Study 11083688 — intervention group
Group type: COMPARATOR
Intervention: Short protocol (fourfold increases in concentration)
Number of subjects: 410
Study 9276784 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 131
Study 9276784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 9276784 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 131
Study 8220399 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate nonparametric tests
Number of subjects: 0
Study 8220399 — intervention group
Group type: EXPERIMENTAL
Intervention: Permutation procedure
Number of subjects: 0
Study 3033751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment radiotherapy and polychemotherapy (C.A.P. + V.D.S.)
Number of subjects: 81
Study 3033751 — intervention group
Group type: COMPARATOR
Intervention: Split‐dose irradiation alone
Number of subjects: 81
Study 29415891 — intervention group
Group type: EXPERIMENTAL
Intervention: gmDC treatment (23 patients)
Number of subjects: 35
Study 29415891 — intervention group
Group type: EXPERIMENTAL
Intervention: gmDC vaccine (12 acute myeloid leukemia patients)
Number of subjects: 35
Study 29415891 — intervention group
Group type: COMPARATOR
Intervention: Standard donor lymphocyte infusion (25 patients)
Number of subjects: 35
Study 29415891 — intervention group
Group type: EXPERIMENTAL
Intervention: gmDC treatment (35 patients total)
Number of subjects: 35
Study 26721228 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional preemptive abdominal contraction (VPAC)
Number of subjects: 32
Study 26721228 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 32
Study 26721228 — intervention group
Group type: COMPARATOR
Intervention: Recurrent LBP group
Number of subjects: 32
Study 25948720 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthiest dietary quintile of modified Alternative Healthy Eating Index
Number of subjects: 27860
Study 25948720 — intervention group
Group type: COMPARATOR
Intervention: Lowest dietary quintile of modified Alternative Healthy Eating Index
Number of subjects: 27860
Study 23589106 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with dendritic cells transduced with wild‐type p53 (Arm B)
Number of subjects: 41
Study 23589106 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination in combination with MDSC targeted therapy with all‐trans‐retinoic acid (ATRA) (Arm C)
Number of subjects: 41
Study 23589106 — intervention group
Group type: COMPARATOR
Intervention: Control (Arm A)
Number of subjects: 41
Study 20608293 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation-oscillation 'On' (Oral-B Triumph with FlossAction brush head)
Number of subjects: 32
Study 20608293 — intervention group
Group type: COMPARATOR
Intervention: Rotation-oscillation 'Off' (used like a manual toothbrush)
Number of subjects: 32
Study 20608293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic 'On' (Sonicare FlexCare with ProResults standard brush head)
Number of subjects: 32
Study 20608293 — intervention group
Group type: COMPARATOR
Intervention: Sonic 'Off' (used like a manual toothbrush)
Number of subjects: 32
Study 18855824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine self-administration sessions (randomized, placebo-controlled)
Number of subjects: 12
Study 18855824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 12
Study 18855824 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence (1 week)
Number of subjects: 12
Study 18855824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use (3 consecutive days)
Number of subjects: 12
Study 18855824 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence (3 days and 17 days)
Number of subjects: 12
Study 18855824 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-night slow-wave activity
Number of subjects: 12
Study 18855824 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient early-night slow-wave activity and late night REM sleep
Number of subjects: 12
Study 16640095 — intervention group
Group type: EXPERIMENTAL
Intervention: salvage regimen associating lopinavir, amprenavir and ritonavir for 26 weeks
Number of subjects: 21
Study 14675918 — intervention group
Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio <10.7%
Number of subjects: 176
Study 14675918 — intervention group
Group type: COMPARATOR
Intervention: F/T-PSA ratio >10.7%
Number of subjects: 176
Study 14675918 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk features (T-PSA >10 ng/ml or Gleason sum >=7)
Number of subjects: 176
Study 14675918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients with F/T-PSA ratio <10.7%
Number of subjects: 176
Study 14675918 — intervention group
Group type: COMPARATOR
Intervention: Low-risk patients with F/T-PSA ratio >10.7%
Number of subjects: 176
Study 10973768 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (40 mg intravenous bolus followed by 60 mg continuous infusion for 48 hours)
Number of subjects: 19725
Study 8827741 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.75 mg.kg‐1
Number of subjects: 49
Study 8827741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31524075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone + AIH
Number of subjects: 14
Study 31524075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 14
Study 29654044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low depressive symptoms (PHQ-9 score: 0-4)
Number of subjects: 1742
Study 29654044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild depressive symptoms (PHQ-9 score: 5-9)
Number of subjects: 1742
Study 29654044 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe depressive symptoms (PHQ-9 score: ≥10)
Number of subjects: 1742
Study 26478277 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training with high PI demands
Number of subjects: 25
Study 26478277 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training with low PI demands
Number of subjects: 25
Study 25313065 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane (50-150 µmol daily for 18 weeks)
Number of subjects: 44
Study 25313065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 21909698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethicon™ PROXIMATE™ ILS™
Number of subjects: 529
Study 18721251 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost given every evening
Number of subjects: 32
Study 18721251 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine/timolol maleate fixed combination (PTFC) given twice daily
Number of subjects: 32
Study 17133211 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0518 100 mg
Number of subjects: 35
Study 17133211 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0518 200 mg
Number of subjects: 35
Study 17133211 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0518 400 mg
Number of subjects: 35
Study 17133211 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0518 600 mg
Number of subjects: 35
Study 17133211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12940591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen
Number of subjects: 24
Study 12940591 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol replacement
Number of subjects: 24
Study 10698133 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (75 mg/kg, maximum 2 g)
Number of subjects: 40
Study 10698133 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg, maximum 10 mg)
Number of subjects: 40
Study 9183723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5-40 micrograms/kg/min)
Number of subjects: 25
Study 9183723 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise (200-400 kg x m/min)
Number of subjects: 25
Study 8170768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatiguing maximal isokinetic quadriceps contractions
Number of subjects: 16
Study 8170768 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 16
Study 2875317 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0
Study 28024882 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil (2.4 gr for 8 weeks)
Number of subjects: 72
Study 28024882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26744910 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0
Study 24091718 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression treatment
Number of subjects: 472
Study 22241604 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of laboratory‐expanded, skin‐derived fibroblasts suspended in autologous plasma
Number of subjects: 32
Study 22241604 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided injection of local anesthetic and physiotherapy
Number of subjects: 32
Study 20531220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (dosing ranged from 12.5 to 300 mg/d)
Number of subjects: 32
Study 20531220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18662592 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 50
Study 18662592 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 50
Study 16277999 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (GT) extract along with a low-energy diet (LED)
Number of subjects: 46
Study 16277999 — intervention group
Group type: COMPARATOR
Intervention: Low-energy diet (LED)
Number of subjects: 46
Study 15328996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceromer resin veneers
Number of subjects: 72
Study 15328996 — intervention group
Group type: COMPARATOR
Intervention: Porcelain veneers
Number of subjects: 72
Study 11042301 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (25 micrograms)
Number of subjects: 60
Study 11042301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8824694 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute propranolol (0.15 mg kg‐1 i.v.)
Number of subjects: 15
Study 8824694 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic propranolol (80 mg three times daily for 2 weeks)
Number of subjects: 15
Study 8824694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1419548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0
Study 1419548 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 1419548 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 0
Study 1419548 — intervention group
Group type: COMPARATOR
Intervention: Lofepramine
Number of subjects: 0
Study 1419548 — intervention group
Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 0
Study 4051686 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus professional psychotherapy
Number of subjects: 110
Study 4051686 — intervention group
Group type: COMPARATOR
Intervention: Paraprofessional drug counseling alone
Number of subjects: 110
Study 29879847 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation programme (3 weeks inpatient stay and 11 weeks home-based activities)
Number of subjects: 0
Study 28031053 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg or 100 mg injections every 4 weeks through week 24
Number of subjects: 356
Study 28031053 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections every 4 weeks through week 24
Number of subjects: 356
Study 25910610 — intervention group
Group type: EXPERIMENTAL
Intervention: High uterosacral vault suspension (HUVS)
Number of subjects: 110
Study 25910610 — intervention group
Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy (SCP)
Number of subjects: 110
Study 25910610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (HUVS and SCP)
Number of subjects: 110
Study 24199972 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian/lemon balm
Number of subjects: 100
Study 24199972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21030049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 326
Study 21030049 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery unrelated to airway or urinary tract)
Number of subjects: 326
Study 19117152 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam
Number of subjects: 90
Study 19117152 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg bupivacaine
Number of subjects: 90
Study 19117152 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90
Study 16752099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (family driving sessions)
Number of subjects: 10
Study 14555269 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 19
Study 11128843 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (groups A + C)
Number of subjects: 112
Study 11128843 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising subjects (groups B + D)
Number of subjects: 112
Study 9201844 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin, 1 mg/kg intravenously in the immediate postoperative period
Number of subjects: 64
Study 9201844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Premarin)
Number of subjects: 64
Study 1492408 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of evening primrose oil and fish oil (GLA, EPA, DHA)
Number of subjects: 0
Study 1492408 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide
Number of subjects: 0
Study 1492408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3103406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 17
Study 3103406 — intervention group
Group type: COMPARATOR
Intervention: DSCG
Number of subjects: 17
Study 3103406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 17
Study 30701988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg on a continuous daily‐dosing regimen)
Number of subjects: 102
Study 30701988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26956689 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant XELOX (capecitabine plus oxaliplatin); capecitabine 1000 mg/m2 twice daily on days 1-14, oxaliplatin 130 mg/m2 on day 1 for eight 3-week cycles
Number of subjects: 100
Study 25952818 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections
Number of subjects: 192
Study 25952818 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) injections
Number of subjects: 192
Study 23250350 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with Achillon(®) device
Number of subjects: 47
Study 23250350 — intervention group
Group type: COMPARATOR
Intervention: Open surgery with Krackow-type sutures
Number of subjects: 47
Study 23250350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 20980493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg folic acid/d
Number of subjects: 172
Study 20980493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg folic acid/d
Number of subjects: 172
Study 20980493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg folic acid/d
Number of subjects: 172
Study 20980493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 19118844 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS program
Number of subjects: 52
Study 17115351 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 plus met
Number of subjects: 255
Study 17115351 — intervention group
Group type: COMPARATOR
Intervention: glarg plus glim
Number of subjects: 255
Study 15646944 — intervention group
Group type: EXPERIMENTAL
Intervention: Flossing in addition to brushing
Number of subjects: 33
Study 15646944 — intervention group
Group type: COMPARATOR
Intervention: No flossing (control)
Number of subjects: 33
Study 11359167 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E (1 g ascorbic acid and 600 IU d-alpha-tocopherol daily before diving)
Number of subjects: 15
Study 11359167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9236432 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d PO for up to 36 days)
Number of subjects: 16
Study 9236432 — intervention group
Group type: COMPARATOR
Intervention: Control (no perindopril, n = 7)
Number of subjects: 16
Study 8179973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg four times a day)
Number of subjects: 49
Study 8179973 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice a day)
Number of subjects: 49
Study 3281529 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-air exercise
Number of subjects: 20
Study 3281529 — intervention group
Group type: COMPARATOR
Intervention: Hot-humid air (sham control)
Number of subjects: 20
Study 3281529 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine rechallenge
Number of subjects: 20
Study 29173997 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced torque (<30Ncm)
Number of subjects: 18
Study 29173997 — intervention group
Group type: COMPARATOR
Intervention: Conventional torque (≥30Ncm)
Number of subjects: 18
Study 26423264 — intervention group
Group type: EXPERIMENTAL
Intervention: New community-based reproductive health intervention model (self-designed handbooks, health lectures, free medical consultations)
Number of subjects: 2100
Study 26423264 — intervention group
Group type: COMPARATOR
Intervention: Traditional community intervention (limited reproductive information and education)
Number of subjects: 2100
Study 25536958 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 190
Study 25536958 — intervention group
Group type: EXPERIMENTAL
Intervention: non-LNG-IUS
Number of subjects: 190
Study 25536958 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 190
Study 24159564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 2708
Study 21429809 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone 12 mg once daily (QD)
Number of subjects: 460
Study 21429809 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone 12 mg every other day (alternate-day dosing)
Number of subjects: 460
Study 21429809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 18329071 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (lornoxicam)
Number of subjects: 100
Study 18329071 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 100
Study 16995554 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 20
Study 16995554 — intervention group
Group type: COMPARATOR
Intervention: epi-LASIK
Number of subjects: 20
Study 12687868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioverter defibrillator with enhancements On
Number of subjects: 89
Study 12687868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioverter defibrillator with enhancements Off
Number of subjects: 89
Study 12687868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioverter defibrillator shock therapy
Number of subjects: 89
Study 12687868 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate shock vector for atrial shock conversions
Number of subjects: 89
Study 12687868 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP on atrial tachyarrhythmias
Number of subjects: 89
Study 12687868 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivered shocks on AF
Number of subjects: 89
Study 12687868 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate shock vector for induced AF
Number of subjects: 89
Study 11155609 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education intervention (1 1/2-hour mandated session + optional self-paced tutorial)
Number of subjects: 100
Study 11155609 — intervention group
Group type: COMPARATOR
Intervention: Control site (no intervention)
Number of subjects: 100
Study 8823558 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg once daily for six weeks
Number of subjects: 71
Study 8823558 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 50 mg once daily for six weeks
Number of subjects: 71